Indeed, if for years, symptomatic drugs, such as pancreatic enzymes and antibiotics, have represented the only available treatment for CF [10], the recent insights into genetics, pathophysiology of CFTR dysfunction, and pharmacology have paved the way for the development of potentially more effective targeted therapies, known as CFTR modulators [11]. This evidence concerns the gene CFTR and cystic fibrosis.